SUBLIVAC FIX Phleum Pratense DT/DRF
Allergic Rhinitis, Allergic Rhinoconjunctivitis
About this trial
This is an interventional treatment trial for Allergic Rhinitis focused on measuring Sublingual immunotherapy, Dose range finding, Dose tolerability, grass pollen, Allergic rhinitis/rhinoconjunctivitis, Safety, Immunogenicity
Eligibility Criteria
Inclusion Criteria:
- Signed informed consent
- Age ≥ 18 ≤ 60 years
- Allergic rhinitis/rhinoconjunctivitis related to grass pollen with or without concomitant mild to moderate persistent asthma
- FEV1 > 70% for patients with a history of asthma, FEV > 70% or PEF > 80% for patients without a history of asthma
- A positive SPT (mean wheal diameter ≥ 3mm compared to negative control and negative control should be negative) for grass pollen assessed within 1 year before randomization.
- Positive serum specific anti-grass IgE-test (> 0.7 U/mL)
- A positive TNPT for grass pollen at screening (Lebel score ≥ 6) at ≤10,000 AU/mL
Exclusion Criteria:
- Patients with (expected) clinically relevant symptoms during the course of the trial due to concomitant sensitization i.e. positive SPT (mean wheal diameter ≥ 3mm) to allergens other than grass pollen
- Patients sensitized to pets should not be included if they are regularly exposed to pets and are symptomatic upon exposure to pets
- Completed immunotherapy (SCIT or SLIT) with grass pollen allergens within the past 5 years
- Completed unsuccessful specific immunotherapy in the past
- Vaccination within one week before start of therapy or during the initiation phase
- Anti-IgE therapy within the 6 months prior to inclusion and during the study
- Severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs
- Active malignancies or any malignant disease during the previous 5 years
- Severe uncontrolled diseases that could increase the risk for patients participating in the study, including but not limited to: cardiovascular insufficiency, any severe or unstable lung diseases, endocrine diseases, clinically significant renal or hepatic diseases, or haematological disorders
- Active inflammation or infection of the target organs (nose, eyes or lower airways) at the start of the study
- Moderate to severe nasal obstructive diseases that preclude a TNPT (septal deviation, nasal polyps, recent nasal surgery, etc.)
- Diseases with a contraindication for the use of Adrenaline (e.g. hyperthyroidism, glaucoma)
- Use of systemic steroids within 4 weeks before start of the study and during the study
- Treatment with systemic and local β-blockers
- Participation in a clinical study with a new investigational drug within the last 3 months or for a biological within the last 6 months prior to or during the study
- Pregnancy, lactation or inadequate contraceptive measures for women of child-bearing age (adequate contraceptive measures will be the use of a contraceptive device or -pill)
- Alcohol, drug or medication abuse within the past year
- Any clinically significant abnormal laboratory parameter at screening
- Lack of cooperation or compliance
- Severe psychiatric, psychological, or neurological disorders
- Patients who are employees of the institution or 1st grade relatives or partners of the investigator
Sites / Locations
- CIMS Studienzentrum Bamberg
- Charité Universitaetsmedizin Berlin Klinik f. Dermatalogie, Venerologie u. Allergologie, Campus Charité Mitte
- Klinik u. Poliklinik f. Dermatologie u. Allergologie Universität Bonn
- Dermatologikum Hamburg - Dept. of Allergology
- HNO Praxis Dr. Horn/Dr. Zeuner
- Klinikum der Johann-Wolfgang-Goethe Universität - Zentrum f. Kinder- u. Jugendmedizin
- Dres.Ina Röhrig-Petering und Holger Petering
- FÄ HNO Allergologie
- Klinikum Stuttgart - Klinik f. Dermatologie u. Allergologie
- Universitäts- Hautklinik Eberhard Karls - Universität Tübingen Department of Dermatology
- Dr. Med. Ulrich Neumann
- Prywatna Praktyka Lekarska Gabinet Pediatryczno-Alergologiczny
- SP-ZOZ Ośrodek Zdrowia w Bieńkówce
- NZOS "Zdrowie"
- Poradnia Alergologiczna Samodzielnego Publicznego Szpitala Nr 5 Slaskiego Uniwersytetu Medycznego w Katowicach
- Poradnia Alergologii i Chorób Płuc SP ZOZ Uniwersytecki Szpital Kliniczny im Norberta Barlickiego w Łodzi
- ALERGOPNEUMA Marek Michnar i Wspolnicy Sp. Jawna
- NZOZ Centrum Alergologii
- Centrum Alergologii Teresa Hofman
- ALERGOMED Specjalistyczna Przychodnia Lekarska Sp. z o.o.
- EMC Intytut Medyczny S.A. Przychodnia przy Łowieckiej
- NZOZ Lekarze Specjaliści J. Małolepszy i Partnerzy
- NZOZ Centrum Alergologii
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Placebo Comparator
Experimental
Experimental
Experimental
Experimental
SUBLIVAC FIX Phleum prat. 0 AUN/ml
SUBLIVAC FIX Phleum prat. 3,333 AUN/ml
SUBLIVAC FIX phleum prat. 10,000 AUN/ml
SUBLIVAC FIX phleum prat. 20,000 AUN/ml
SUBLIVAC FIX Phleum prat. 40,000 AUN/ml
Evaluation of the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml by an independent safety committee
Start of SUBLIVAC FIX Phleum prat. 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml arm evaluated by an independent safety committee